REG - Physiomics PLC - Update regarding CEO - Peter Sargent

PhysiomicsAnnouncement

15/05/2026 07:01

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260515:nRSO4298Ea&default-theme=true

RNS Number : 4298E  Physiomics PLC  15 May 2026

15 May 2026

 

Physiomics plc

 

("Physiomics" or the "Company")

 

Update regarding CEO - Peter Sargent

 

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and
biostatistics company supporting the development of new therapeutics and
personalised medicine solutions, is pleased to announce that Peter Sargent has
agreed to extend his existing agreement with the Company and remain in his
current role throughout June 2026.

 

The Board and Dr Sargent remain in ongoing discussions regarding a potentially
longer-term continuation of his involvement, in relation to which further
updates will be provided in due course.

 

The Board acknowledges Dr Sargent's professionalism and contribution during a
period of considerable change within the business and looks forward to
continuing what has become a productive working relationship.

 

Nick Tulloch, Chairman of Physiomics plc, commented:  "In the short time we
have worked with Pete, he has diligently overseen the operations of Physiomics
and, in particular, has handled the management transition of the business with
evident skill and sensitivity. Pete has been a considerable support to the new
Board and we are delighted that he is willing to continue in his role for the
time being whilst we develop plans for growth and expansion of the Company."

 

ENDS

 

For more information about Physiomics and its services, please visit
www.physiomics.co.uk (http://www.physiomics.co.uk) .

 

Enquiries:

 Physiomics plc                    Email:  info@physiomics.co.uk

 Mike Whitlow

 Strand Hanson Ltd (NOMAD)         Tel:  +44 (0) 20 7409 3494

 James Dance & James Bellman

 Hybridan LLP (Broker)             Tel:  +44 (0) 20 3764 2341

 Claire Louise Noyce

 

About Physiomics

 

Physiomics plc combines expertise across Modelling & Simulation,
Biostatistics, Data Science and Bioinformatics, together with deep biology
expertise, to help biotech and pharma companies streamline their drug
development journeys. Our approach is to help derive insight from all relevant
and often disparate data in order to de-risk decision making and optimise
research design across discovery, pre-clinical and clinical studies. Through
use of cutting- edge computational tools, bespoke models and our proprietary
Virtual Tumour technology, the Physiomics team has informed the development of
over 140 commercial projects, with over 125 targets and drugs modelled.
Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics
& CRUK.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDAIMPTMTTBBJF



            Copyright 2019 Regulatory News Service, all rights reserved